MN-SMITHS-MEDICAL
4.5.2021 14:02:10 CEST | Business Wire | Press release
Smiths Medical, a global medical device leader, today announced it has formed an exclusive partnership with Ivenix, Inc. that positions the companies as the first in the U.S. to offer a comprehensive suite of infusion management solutions to meet healthcare needs across the continuum of care. The long-term partnership, which includes a strategic investment from Smiths Medical, unites two innovators under a common goal of revolutionizing infusion management to improve patient safety and meet the needs of healthcare providers today and into the future.
Ivenix, a medical technology company dedicated to eliminating infusion-related patient harm, developed the first and only large-volume infusion pump from the ground up to meet the latest U.S. Food and Drug Administration infusion pump guidelines addressing recurring safety issues with pumps. Ensuring patient safety and clinical efficiency are critical components of successful life-saving infusion management. Today, infusion-related errors account for more than 50% of the 1.5 million adverse drug events reported annually to the FDA,1 and infusion-related adverse drug events cost the healthcare system more than $2 billion annually.2
Smiths Medical’s complementary portfolio of market-leading infusion systems CADD® -Solis and Medfusion® include syringe and ambulatory pumps that serve adult and neonatal critical care, operating rooms, and pain management in both the hospital and home. By adding the Ivenix Infusion System to its U.S. product portfolio, Smiths Medical will accelerate its offering into the large-volume infusion device segment, which is estimated to be over $2 billion.
“As a researcher focused on large volume IV smart pumps, I am well aware of the many safety and usability issues that exist with current products,” said Karen K. Giuliano, Ph.D., RN, FAAN, MBA, an Associate Professor and Co-director of the Nursing-Engineering Center for Innovation at the University of Massachusetts Amherst. “Innovation in IV smart pumps is long overdue, and I am happy to see new options for acute care clinicians to consider for the delivery of life-saving fluids and medications in this very important area of patient safety.”
“The long-term partnership between Smiths Medical and Ivenix will ensure that we are bringing the next generation of infusion management solutions to hospitals across the U.S. and fulfills our commitment to helping connect patients to life-saving therapies and insights to providers,” said JehanZeb Noor, Smiths Medical CEO. “Our investment in Ivenix will help spur the research and development needed to continue building on this critical resource and provide holistic solutions for hospitals and health systems.”
The Ivenix Infusion System includes a large-volume infusion pump with administration sets, infusion management tools and analytics to inform care and advance efficiency. The system received 510(k) clearance in 2019 and sets a new standard in infusion delivery by rethinking safety, simplicity, and interoperability. The system is centered around both the patient and clinician and designed to reduce infusion-related errors and drive down the total cost of ownership.
“This partnership allows us to accelerate the commercial reach of our infusion platform, and together provide a portfolio of leading-edge infusion solutions to deliver the highest standard of safe and integrated infusion care,” said Ivenix CEO Jorgen B. Hansen.
Smiths Medical will launch the Ivenix infusion System as part of its infusion portfolio in the summer of 2021.
About Smiths Medical
A leading innovator of specialized medical technologies for global markets, focusing on the medication delivery, vital care, and safety devices market segments. For more information, visit www.smiths-medical.com .
About Ivenix
Ivenix, Inc. is a medical technology company with a vision to eliminate infusion-related patient harm. The company was founded to develop innovative solutions that transform infusion delivery. Ivenix designed an infusion system from the ground up to streamline medication delivery and bring infusion technology into the digital age. The Ivenix Infusion System includes a large-volume infusion pump supported by a robust infusion management system designed to set new standards in simplicity, intelligence, and reliability. For more information, visit ivenix.com . The Ivenix Infusion System is cleared by the FDA.
References:
- FDA report, data on file
- ODPHP. Health Care Quality and Patient Safety: Adverse Drug Events. 2017
View source version on businesswire.com: https://www.businesswire.com/news/home/20210504005275/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa Opens the Door to AI-Driven Shopping for Businesses Worldwide8.4.2026 18:00:00 CEST | Press release
Part of the Visa Intelligent Commerce portfolio, Intelligent Commerce Connect will enable more ways for agents to pay and merchants to accept agentic transactions in a single integrationCurrently in pilot with select partners including Aldar, AWS, Diddo, Highnote, Mesh, Payabli, Sumvin, and rolling out to more partners this year Visa Inc. (NYSE: V) today unveiled Intelligent Commerce Connect, a new solution that makes it easier for businesses to connect to and participate in AI-powered commerce. Intelligent Commerce Connect acts as a network, protocol, and token vault-agnostic ‘on ramp’ to agentic commerce for agent builders, merchants, and enablers. As consumers increasingly rely on AI agents to make purchases, businesses – whether they are building agents, selling to them, or processing transactions – need a simple way to get started. Intelligent Commerce Connect, part of the Visa Intelligent Commerce portfolio, meets that need. Through a single integration via the Visa Acceptance Pl
Sumitomo Corporation, SMBC Aviation Capital, Apollo and Brookfield Complete the Acquisition of Air Lease Corporation8.4.2026 15:13:00 CEST | Press release
Sumitomo Corporation, SMBC Aviation Capital, Apollo-managed funds (“Apollo”) and Brookfield today announced that they have completed the previously announced acquisition of Air Lease Corporation (“Air Lease”) and have renamed the business Sumisho Air Lease Corporation (“Sumisho Air Lease”). This transformational transaction improves the financial position of the business with long term support and aviation expertise from co-investors Sumitomo Corporation, SMBC Aviation Capital, Apollo and Brookfield. Sumisho Air Lease’s strong foundation as an established aircraft lessor, supported by SMBC Aviation Capital’s industry‑leading capabilities as servicer, creates a platform with the scale and financial strength needed to meet the fast‑changing and increasingly complex requirements of airline customers. Sumisho Air Lease will also benefit from the deep expertise and long-standing commitment that both Sumitomo Corporation and SMBC Aviation Capital bring to the global aviation leasing sector.
Sitetracker Launches Scout, an Agentic AI Platform Purpose-Built for Critical Infrastructure8.4.2026 15:00:00 CEST | Press release
Sitetracker, the leading Asset Lifecycle Management platform for critical infrastructure, today announced the launch of Scout, its new Agentic AI platform designed to help infrastructure owners, operators, and contractors gain deep insights and drive automation within their operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408923336/en/ Scout, ready for real work As your AI analyst and agent, Scout is ready to work on day 1. Scout provides clarity when decisions are forming and momentum when action is required. It surfaces risk, synthesizes information, and helps accelerate execution by connecting data and driving action. Scout creates operational intelligence and turns it into action all in a secure environment that protects data sovereignty. “Our customers are looking to create compounding competitive advantages,” said Giuseppe Incitti, Chief Executive Officer of Sitetracker. “Scout delivers by providing easy t
Westinghouse Hosts Annual VVER Fuel Forum with Customers8.4.2026 15:00:00 CEST | Press release
Westinghouse currently has fuel supply contracts with all the European VVER operators Westinghouse and MVM Paks Nuclear Power Plant (NPP) recently co-hosted the VVER Fuel Forum in Budapest to share insights and plans for the continued deployment of VVER-1000 and VVER-440 fuel in operating reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408646373/en/ Participants to the VVER Fuel Forum Péter János Horváth, CEO of MVM Paks, welcomed all the participants, highlighting that Hungary is ending two decades of single supplier fuel dependency thanks to the agreement recently signed with Westinghouse to supply the VVER-440 NOVA E-6 fuel design. Six customers presented the progress made and positive outcomes achieved in the past years with the introduction of Westinghouse fuel into mixed cores with resident fuel in their reactors: Energoatom has extensive experience with Westinghouse VVER-440 and VVER-1000 fuel, currently u
Virica Biotech and FUJIFILM Biosciences Collaborate Under the Canada–Japan Co‑Innovation Program to Advance AAV Production Enhancers8.4.2026 15:00:00 CEST | Press release
Efficient production of Adeno-Associated Virus (AAV) vectors at scale for in vivo gene therapies remains a key bottleneck for broad patient access and sustainable manufacturing costs.Virica and FUJIFILM Biosciences will co-develop an off-the-shelf enhancer–media solution to boost AAV yields and process robustness in FUJIFILM Biosciences BalanCD® HEK293 system. Virica Biotech (“Virica”), a cell enhancer company specializing in Viral Sensitizers (VSE™) for viral vector manufacturing, today announced it is receiving advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), under the Canada–Japan Corporate Co-Innovation Program for a collaboration with FUJIFILM Biosciences. The collaboration will focus on optimizing a VSE™ formulation for FUJIFILM Biosciences BalanCD HEK293 media to support academic and commercial AAV producers globally. AAV vectors are a cornerstone of in vivo gene delivery for gene therapies, but they re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
